Chimeric antigen receptor T cells against the IGHV4-34 B cell receptor specifically eliminate neoplastic and autoimmune B cellsIvan Cohen, Kostas Stamatopoulos, Huiwu Zhao et al.|Science Translational Medicine|2026Cited by 10
Precision targeting of pathogenic B cells and autoantibodies in systemic lupus erythematosus using CAR T cells against the IGHV4-34 B cell receptorAudrey Bochi-Layec, Marco Ruella, Ivan Cohen et al.|Blood|2025Cited by 0
Polatuzumab vedotin–containing regimens as bridge to CART: analysis from the CART-SIE studyGiulia Gabrielli, Pier Luigi Zinzani, Beatrice Casadei et al.|Blood Advances|2026Cited by 0